Multimedialna platforma wiedzy medycznej Internetowa Księgarnia Medyczna Kalendarium Konferencji
Endokrynologia Polska
MENU
Shortcuts Submit an article Author Guidelines Polish Society of Endocrinology Reviewers 2022 Redeem voucher Abstracts, 5–7 May 2022, Gliwice

open access

Vol 63, No 4 (2012)
Case report
Submitted: 2013-02-15
Published online: 2012-08-30
View PDF Download PDF file
Get Citation

Normal bone turnover markers in a patient with active Paget’s disease of bone: response to treatment with zoledronic acid

Stergios A. Polyzos, Athanasios D. Anastasilakis, Panagiotis Anagnostis, Marina Kita, Georgios Arsos, Efstratios Moralidis, Athanasios Papatheodorou, Evangelos Terpos
Endokrynol Pol 2012;63(4):312-315.

open access

Vol 63, No 4 (2012)
Case report
Submitted: 2013-02-15
Published online: 2012-08-30

Abstract

The treatment of Paget’s disease of bone (PDB) aims at the suppression of abnormal bone turnover; bisphosphonates are currently the treatment of choice. Indications for antiresorptive treatment in symptomatic patients with PDB include bone or joint pain, neurological complications, surgery planned at an active pagetic site and hypercalcaemia from immobilisation. The goals of antiresorptive treatment are clinical improvement and biochemical remission, as assessed by the normalisation of bone turnover markers. Clinical deterioration, especially bone pain, should be considered before deciding to treat patients with late sclerotic (burned-out) PDB. Bone scintigraphy may be of importance in these patients, because it depicts increased osteoblastic activity, when bone markers may not. We present a case of late sclerotic PDB with clinical deterioration but normal bone turnover markers, who experienced significant clinical improvement after treatment with zoledronic acid.

Abstract

The treatment of Paget’s disease of bone (PDB) aims at the suppression of abnormal bone turnover; bisphosphonates are currently the treatment of choice. Indications for antiresorptive treatment in symptomatic patients with PDB include bone or joint pain, neurological complications, surgery planned at an active pagetic site and hypercalcaemia from immobilisation. The goals of antiresorptive treatment are clinical improvement and biochemical remission, as assessed by the normalisation of bone turnover markers. Clinical deterioration, especially bone pain, should be considered before deciding to treat patients with late sclerotic (burned-out) PDB. Bone scintigraphy may be of importance in these patients, because it depicts increased osteoblastic activity, when bone markers may not. We present a case of late sclerotic PDB with clinical deterioration but normal bone turnover markers, who experienced significant clinical improvement after treatment with zoledronic acid.

Full Text:

View PDF Download PDF file
Get Citation

Keywords

bisphosphonate; bone scintigraphy; bone-specific alkaline phosphatase; C-terminal telopeptide of type I collagen; Paget’s disease of bone; zoledronic acid

About this article
Title

Normal bone turnover markers in a patient with active Paget’s disease of bone: response to treatment with zoledronic acid

Journal

Endokrynologia Polska

Issue

Vol 63, No 4 (2012)

Article type

Case report

Pages

312-315

Published online

2012-08-30

Page views

580

Article views/downloads

1138

Bibliographic record

Endokrynol Pol 2012;63(4):312-315.

Keywords

bisphosphonate
bone scintigraphy
bone-specific alkaline phosphatase
C-terminal telopeptide of type I collagen
Paget’s disease of bone
zoledronic acid

Authors

Stergios A. Polyzos
Athanasios D. Anastasilakis
Panagiotis Anagnostis
Marina Kita
Georgios Arsos
Efstratios Moralidis
Athanasios Papatheodorou
Evangelos Terpos

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Via MedicaWydawcą jest  VM Media Group sp. z o.o., Grupa Via Medica, ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl